Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people.

AIMS: To investigate associations between HMG-CoA reductase inhibitor (statin) use and muscle strength, balance, mobility and falls in older people. METHODS: Five hundred community-dwelling people aged 70-90 years provided information about their medication use and undertook tests of lower limb strength, postural sway, leaning balance (maximal balance range and coordinated stability tests) and functional mobility. Participants were then followed up for 12 months with respect to falls. RESULTS: After adjusting for general health in analyses of covariance procedures, statin users had poorer maximal balance range than non-statin users (P = 0.017). Statin and non-statin users did not differ with respect to strength, postural sway, mobility or falls experienced in the follow-up year. CONCLUSION: In a sample of healthy older people, statin use was not associated with muscle weakness, postural sway, reduced mobility or falls. Statin users, however, had poorer leaning balance which may potentially increase fall risk in this group.

[The QuIK-Registry of the German Society of Cardiologists in private practice: countrywide and benchmarking quality assurance in invasive cardiology]. / Das QuIK-Register des Bundesverbands Niedergelassener Kardiologen. Flächendeckende vergleichende Qualitätssicherung in der Invasivkardiologie.

QuIK is the German acronym for QUality Assurance in Invasive Cardiology. It describes the continuous project of an electronic data collection in Cardiac catheterization laboratories all over Germany. Mainly members of the German Society of Cardiologists in Private Practice (BNK) participate in this computer based project. Since 1996 data of diagnostic and interventional procedures are collected and send to a registry-center where a regular benchmarking analysis of the results is performed. Part of the project is a yearly auditing process including an on-site visit to the cath lab to guarantee for the reliability of information collected. Since 1996 about one million procedures have been documented.

[Care of hypertensive patients seen by cardiologists: results of the Snapshot Hypertension Registry]. / Der Patient mit arterieller Hypertonie in der kardiologischen Facharztpraxis: Ergebnisse des Snapshot-Hypertonie-Registers. Ein Projekt des Bundesverbandes Niedergelassener Kardiologen (BNK e.V.).

BACKGROUND: The objective of the Snapshot Hypertension Registry (SHR) was to assess the quality of antihypertensive drug treatment in hypertensive patients seen by cardiologists on three consecutive days in December 2005. METHODS: Full data sets were obtained for 7302 patients (89.9% of total returned) seen by 268 cardiologists. Mean age of hypertensive patients was 65.4 +/- 11.2 years, 62 % were male, and 93 % were referred to the cardiologist by a general practitioner. RESULTS: Judging from their casual ("snapshot") blood pressure, 35.3 % were well treated (< 140/90 mm Hg). According to the 24-hour ambulatory blood pressure even a lower rate of hypertensive patients, namely 27.6 %, had their blood pressure well controlled (< 130/80 mm Hg). Of all patients, 24 % were on monotherapy. Only 33.7 % of the patients on monotherapy were normotensive. Of all patients on a combination of drugs 36.9 % were normotensive according to the casual blood pressure measurements. Private patients were prescribed angiotensin receptor blockers more frequently than patients who only had statutory health insurance. CONCLUSIONS: The Snapshot Registry analysis revealed that the casual blood pressure in the majority of hypertensive patients who were reviewing antihypertensive medication was not in the normotensive range. In addition, our data demonstrate that evidence-based antihypertensive medication was often not adequately used in Germany.

[5th Report of the German Association of Cardiologists in Private Practice (BNK) on Quality Assurance in Cardiac Catheterization and Coronary Intervention 2003-2005]. / 5. Bericht des Bundesverbandes Niedergelassener Kardiologen zur Qualitätssicherung in der diagnostischen und therapeutischen Invasivkardiologie 2003-2005.

On behalf of the German Association of Cardiologists in Private Practice (BNK) the Steering Committee of the QuIK Registry reports on the results of the voluntary quality assurance in invasive cardiology in 2003-2005 and compares it to other data collections. In 2005 more than 70% of diagnostic (LHK) and 78% of therapeutic (PCI) cardiac catheterization procedures in private practice were entered into the registry. Altogether 229,462 LHK and 64,818 PCI were documented over the 3 years. In the reported period age of patients, percentage of acute coronary syndromes and three-vessel coronary artery disease increased in LHK as well as in PCI while consumption of contrast media and fluoroscopy time decreased. By implemented possibility of follow-up, a high rate of external auditing (monitoring) and certification QuIK remains a worldwide unique quality assurance project in cardiology. On a stable data basis over 10 years the QuIK Registry enables the implementation of quality indicators for future quality assurance purposes.

Using a clinical pathway and education to reduce inappropriate prescribing of enoxaparin in patients with acute coronary syndromes: a controlled study.

AIMS: To evaluate efficacy of a pathway-based quality improvement intervention on appropriate prescribing of the low molecular weight heparin, enoxaparin, in patients with varying risk categories of acute coronary syndrome (ACS). METHODS: Rates of enoxaparin use retrospectively evaluated before and after pathway implementation at an intervention hospital were compared to concurrent control patients at a control hospital; both were community hospitals in south-east Queensland. The study population was a group of randomly selected patients (n = 439) admitted to study hospitals with a discharge diagnosis of chest pain, angina, or myocardial infarction, and stratified into high, intermediate, low-risk ACS or non-cardiac chest pain: 146 intervention patients (September-November 2003), 147 historical controls (August-December 2001) at the intervention hospital; 146 concurrent controls (September-November 2003) at the control hospital. Interventions were active implementation of a user-modified clinical pathway coupled with an iterative education programme to medical staff versus passive distribution of a similar pathway without user modification or targeted education. Outcome measures were rates of appropriate enoxaparin use in high-risk ACS patients and rates of inappropriate use in intermediate and low-risk patients. RESULTS: Appropriate use of enoxaparin in high-risk ACS patients was above 90% in all patient groups. Inappropriate use of enoxaparin was significantly reduced as a result of pathway use in intermediate risk (9% intervention patients vs 75% historical controls vs 45% concurrent controls) and low-risk patients (9% vs 62% vs 41%; P < 0.001 for all comparisons). Pathway use was associated with a 3.5-fold (95% CI: 1.3-9.1; P = 0.012) increase in appropriate use of enoxaparin across all patient groups. CONCLUSION: Active implementation of an acute chest pain pathway combined with continuous education reduced inappropriate use of enoxaparin in patients presenting with intermediate or low-risk ACS.

Development of a probabilistic blood lead prediction model.

A partially probabilistic blood lead prediction model has been developed, based on the US Environmental Protection Agency integrated exposure-uptake-biokinetic blood lead model (IEUBK model). This study translated the IEUBK model into a spreadsheet format. The uptake submodel incorporates uncertainty distributions for exposure and bioavailability parameters. The biokinetic submodel is duplicated with a table incorporating partitioning and decay of lead levels in the body. As a case study, the probabilistic model is applied to a lead exposure scenario involving a former smelter site in Sandy, Utah. The probabilistic model produces less biased estimates of means and standard deviations than the deterministic model. Parameter uncertainty is propagated in the model by the use of Monte Carlo simulation. Thus, sensitivity analysis is possible, and driving variables can be determined.

Excimer laser coronary angioplasty: experience with a prototype multifibre catheter in patients with stable angina pectoris.

Percutaneous excimer laser coronary angioplasty (ELCA) was performed in a first group of 20 patients with stable angina pectoris caused by significant coronary stenosis, and long-term follow-up was evaluated. Prototype 4 to 5.5 French multifibre catheters with 18-20 quartz fibres of 100 microns diameter, concentrically arranged around a central lumen for taking up a guide wire, were coupled to a commercial XeCl excimer laser. Energy was delivered at a wavelength of 308 nm with a pulse duration of 60 or 120 ns. Operating at a repetition rate of 20 Hz, mean energy transmission was 13.4 +/- 6.8 mJ per pulse. In all but one patient the lesion could be passed by the catheter. Percent diameter stenosis decreased from 77.1 +/- 10.8% to 53.1 +/- 11.8% after ELCA. Complications were frequently observed, intracoronary thrombus formation in eight instances, dissection in six patients and spasm in five cases, causing total vessel occlusion in five procedures. All complications could be managed efficaciously by thrombolytic and vasodilating drugs and/or balloon angioplasty. Subsequent PTCA was performed in case of complication or insufficient stenosis reduction after ELCA in 18 patients with adequate results (residual stenosis, 28.5 +/- 10.2%). Long-term follow-up angiography, which could be performed in 16 of 19 laser treatments, demonstrated significant restenosis in only three patients. Our preliminary results suggest that, using ELCA, ablation of atherosclerotic lesions is feasible in most cases. However, compared with PTCA, stenosis reduction is significantly less, and the acute complication rate is much higher. Thus, further improvements of the catheter system are necessary in order to realize the advantages of excimer laser ablation, which can be demonstrated by experimental studies.

[Angioplasty using high-frequency energy in coronary stenosis]. / Angioplastie mittels Hochfrequenzenergie bei Koronararterienstenosen.

The most notable limitations of balloon dilatation, acute vascular occlusion with a rate of 3 to 5% and restenosis rate of 20 to 40%, appear at least partially attributable to the mechanism of luminal widening--tearing of the intima and plastic restructuring of plaque material. Alternative angioplasty methods, with the exception of stent implantation, are based on the concept of rendering plaque material, by excision and ablation, with a smoother and less thrombogenic interior surface and to lower the risk of renewed proliferation. Plaque material is removed in three ways: mechanical, by excision; thermically, by laser with relatively low energy density or by high-frequency alternating current; non-thermically, by photoablation with laser of very high energy impulse density. High-frequency alternating current as an energy source for thermic angioplasty is used in four technically different forms of application (Table 1): as indirect or direct high-frequency angioplasty in the scope of the "spark erosion" technique and for heating a balloon during balloon dilatation to achieve thermofusion of the tissue for stabilization of the angioplasty results. With indirect hot-tip high-frequency angioplasty the high-frequency alternating current is employed to rapidly heat an olive-shaped fully isolated metal tip with an integrated resistor, plated with gold to avoid adhesion of thrombotic material. The heat emitted is directed radially. The currently-available system consists of a 20-Watt high-frequency generator with 5 MHz. On application of 10 Watts to tissue in water at 37 degrees C, the temperature achieved at the catheter tip is 130 to 140 degrees C.(ABSTRACT TRUNCATED AT 250 WORDS)

Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure--a placebo-controlled trial.

To evaluate the acute and chronic effects of diuretic monotherapy with 3 mg piretanide bid, 46 patients (pts) with congestive heart failure (NYHA II-III) secondary to coronary artery disease were studied. Within 3 weeks of therapy, the patients lost 1.6 kg body weight. Forty-four patients reported a subjective feeling of improvement. Echocardiographically, a highly significant (p less than 0.001) reduction of diastolic and systolic diameters was found, as well as an increase of fraction shortening. Chest x-ray indicated a reduction of heart volume from 1012 +/- 263 ml to 936 +/- 233 ml (p less than 0.001). The serum potassium level remained unchanged. A subgroup of 26 pts underwent invasive hemodynamic examinations. IV injection of 6 mg piretanide resulted in an acute reduction of pulmonary wedge pressure (pc) from 20.2 +/- 5.3 mmHg to 11.9 +/- 5.0 mmHg (p less than 0.001); simultaneously a slight decrease of cardiac index from 3.2 +/- 0.6 l/min/m2 to 3.0 +/- 0.4 l/min/m2 was observed. Invasive control after 3 weeks of oral therapy showed no decline of the piretanide effect. The exercise tolerance increased clearly from 135 +/- 161 Wmin to 249 +/- 268 Wmin (p less than 0.05). A control group of further 14 pts was treated with placebo only and did not show any significant changes of pc (20.0 +/- 6.4 mmHg vs. 22.8 +/- 19.2 mmHg), exercise tolerance, or other clinical parameters. Thus, the diuretic monotherapy of congestive heart failure with piretanide is highly effective and shows a significant improvement in all clinical and hemodynamic parameters in the absence of any remarkable side effects.

Hemodynamic profile of carvedilol.

Several so-called multiple-action compounds have been developed, such as medroxalol (alpha and beta blockade, and beta-2 stimulation), celiprolol (alpha-2 and beta-1 blockade, and beta-2 stimulation) and carvedilol (beta blockade and vasodilatation) for the treatment of patients with arterial hypertension and with coronary heart disease. Carvedilol exerts relatively uniform peripheral effects, i.e. a reduction of both systolic and diastolic blood pressure at rest and during exercise, and a decrease in the resting and exercise heart rate. Blood pressure fall due to carvedilol may be induced by its vasodilating effect, as documented by measurements of forearm blood flow and peripheral vascular resistance. Moreover, renal hemodynamics does not seem to be significantly altered by carvedilol. Carvedilol may also produce an improvement of the LV contractile status in patients with CHD and impaired LV function, mainly due to afterload reduction, in addition to its antianginal effect, which is due mainly to the beta-blocking properties of this substance. From the studies mentioned it may be concluded that carvedilol is a useful and promising drug for treating patients with both arterial hypertension and with coronary artery disease.

[The effect of a combination of ridazolol and molsidomine on hemodynamics and left ventricular function in dilated cardiomyopathy]. / Einfluss einer Kombination von Ridazolol und Molsidomin auf Hämodynamik und linksventrikuläre Funktion bei dilatativer Kardiomyopathie.

Haemodynamics and Left Ventricular Function in Patients with Dilated Cardiomyopathy after a Combination of Ridazolol and Molsidomine. To evaluate the haemodynamic properties of the new beta-blocker ridazolol alone and in combination with the vasodilator molsidomine a randomized study was carried out in 12 patients with dilated cardiomyopathy (NYHA II/III). beta-Blockade leads to a decreasing tendency in blood pressure and heart rate. Pulmonary capillary wedge pressure (PC) was not significantly altered and ejection fraction remained unchanged. Molsidomine showed a decrease of PC. The combination of both drugs revealed both the positive haemodynamic effects of molsidomine and the reduced heart rate of beta-blockade. Negative side effects could not be observed.

Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.

Pharmacokinetics and systemic effects of recombinant tissue-type plasminogen activator (rt-PA) were determined during coronary thrombolysis in 12 acute myocardial infarction patients using a consecutive intravenous infusion regimen. Ten mg rt-PA were infused in 2 minutes resulting in a peak plasma concentration (mean +/- SD) of 3310 +/- 950 ng/ml, followed by 50 mg in 1 h and 30 mg in 1.5 h yielding steady state plasma levels of 2210 +/- 470 ng/ml and 930 +/- 200 ng/ml, respectively. All patients received intravenous heparin. Total clearance of rt-PA was 380 +/- 74 ml/min, t1/2 alpha was 3.6 +/- 0.9 min and t1/2 beta was 16 +/- 5.4 min. After 90 min, in plasma samples containing anti-rt-PA-IgG to inhibit in vitro effects, fibrinogen was decreased to 54%, plasminogen to 52%, alpha 2-antiplasmin to 25%, alpha 2-macroglobulin to 90% and antithrombin III to 85% of initial values. Coagulation times were prolonged and fibrin D-dimer concentrations increased from 0.40 to 2.7 micrograms/ml. It is concluded that pharmacokinetics of rt-PA show low interpatient variability and that its short mean residence time in plasma allows precise control of therapy. Apart from its moderate effect on the haemostatic system, rt-PA appears to lyse a fibrin pool in addition to the coronary thrombus.

Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).

The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomized multicenter trial in 246 patients with acute myocardial infarction of less than 6 h duration. Both 70 mg of single chain rt-PA with an initial bolus of 10 mg and 3 million units of urokinase with an initial bolus of 1.5 million units were given intravenously over 90 min. The first angiographic study at the end of the infusion revealed a patent infarct-related artery (Thrombolysis in Myocardial Infarction trial [TIMI] grade 2 or 3) in 69.4% of 121 patients given rt-PA versus 65.8% of 117 patients given urokinase (p = NS). Among patients treated within 3 h from symptom onset a patent infarct-related artery was found in 63.9% of 72 patients given rt-PA versus 70% of 70 patients given urokinase (p = NS). There were five cardiac deaths in each group and one fatal intracranial hemorrhage in the rt-PA group. The in-hospital reinfarction rate was 8.9% versus 13.2% for patients treated with rt-PA and urokinase, respectively. There was no difference in left ventricular function at baseline and follow-up catheterization studies. Both drugs were well tolerated and there was no significant difference in cardiovascular or bleeding complications between the two groups. It is concluded that rt-PA and urokinase in the dosages used provide similar efficacy and safety in the treatment of acute myocardial infarction. Reocclusion during the first 24 h may be less frequent after urokinase treatment.

[Hemodynamics and ventricular function in dilated cardiomyopathies following administration of the new beta-blocker ridazolol]. / Hämodynamik und Ventrikelfunktion bei dilatativen Kardiomyopathien nach Gabe des neuen Betablockers Ridazolol.

Recent reports in the literature indicate that beta-blockade may improve survival in patients with dilated cardiomyopathy (DCMP). This goal can obviously not be attained if the beta-blocker employed effects deleterious actions on the left ventricular function or hemodynamics. Accordingly, to assess the suitability of the new beta-blocker ridazolol for use in this regard, in nine patients with DCMP NYHA class II/III, studies were performed (by means of balloon-tipped pulmonary artery catheter and radionuclide ventriculography) at rest and during exercise prior to and one hour after oral administration of a 40 mg-dose of the agent. At rest, there was a decreasing tendency in systolic blood pressure from 123 +/- 18.5 mm Hg to 113 +/- 15.2 mm Hg and heart rate from 94 +/- 19 beats/min to 83 +/- 17 beats/min. Pulmonary capillary wedge pressure was not significantly altered at 16.2 +/- 7.9 mm Hg and 17.1 +/- 8.4 mm Hg, respectively. Ejection fraction remained unchanged with 29 +/- 14%. The slight decrease in cardiac output from 5.1 +/- 1.3 l/min to 4.5 +/- 1.3 l/min was not significant. During exercise, there were also decreasing tendencies in the heart rate from 128 +/- 21 beats/min to 102 +/- 22 beats/min and the systolic blood pressure from 148 +/- 20.5 mm Hg to 141 +/- 18.4 mm Hg. Essentially unchanged were the pulmonary capillary wedge pressure (26.1 +/- 7.2 mm Hg/27.8 +/- 5.0 mm Hg) and ejection fraction (30 +/- 10%/27 +/- 8%) during exercise.(ABSTRACT TRUNCATED AT 250 WORDS)

[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)]. / Intravenöse Infusion von recombinant tissue plasminogen activator (rt-PA) und Urokinase beim akuten Myokardinfarkt: Zwischenergebnisse der G.A.U.S.-Studie (German Activator Urokinase Study).

The effects of recombinant tissue plasminogen activator (rt-PA) and urokinase on patency and early reocclusion of infarct-related coronary arteries were investigated in a single blind, randomised multicenter trial in up to now 125 patients with acute myocardial infarction of less than six hours duration. Both, 70 mg of single-chain rt-PA with an initial bolus of 10 mg, and 3 million U of urokinase with an initial bolus of 1,5 million U were given intravenously over 90 minutes. The first angiogram at the end of the infusion revealed a patent infarct-related artery (TIMI grade 2 or 3) in 68% of 62 patients with rt-PA vs. 63% of 63 patients with urokinase (n.s.). Twenty-four hours later patent infarct-related arteries occurred in the same frequency in the rt-PA group and in the urokinase group (71.5% vs. 74.6%, n.s.), although additional recanalisation procedures in sequence with the first angiography were performed more frequent in the rt-PA group. There were two cardiac deaths in either group. In-hospital reinfarction rate was 9.7% vs. 17.5% for patients treated with rt-PA and urokinase, respectively. Both drugs were well tolerated, no significant difference of cardiovascular or bleeding complications could be observed between the two groups. It is concluded that rt-PA and urokinase in the dosages used provide similar efficiency and safety in the treatment of acute myocardial infarction.

Long term inotropic effects of flecainide and propafenone.

This study was undertaken to evaluate the effect of flecainie (Fle) and propafenone (Pro) on rest and exercise myocardial contractility after prolonged oral administration. Standardized, fully automated, gated radionuclide angiograms at rest and during maximum exercise were performed single blinded and prospectively in 19 patients before and after oral treatment with either 150 mg b.i.d. of Fle or 150 mg t.i.d. of Pro. The left ventricular ejection fraction (EF%) as a hemodynamic indicator presented as follows: (Table: see text) In general, there was no significant effect of either drug on resting ventricular function. In only one patient of the Fle group with decreased baseline function did the left ventricular EF fall from 40% to 29%. During exercise, ventricular performance showed deterioration in the Pro group, but, interestingly, improvement in the Fle group. As a result of these opposite changes, the effect of the two drugs on the exercise response of ventricular function was significantly different (P less than 0.05). This study thus gives first evidence that no significant cardiodepressive effects are to be expected after prolonged application of Fle or Pro in normal hearts. There might even be a mild beneficial effect on exercise performance after Fle.

[Endocarditis caused by Haemophilus parainfluenzae and Neisseria gonorrhoeae]. / Endokarditis durch Haemophilus parainfluenzae und Neisseria gonorrhoeae.

Infective endocarditis due to gramnegative bacteria is rare. Overall, its relative frequency seems to be much lower than 10 percent. According to the extensive literature reviewed most often the causative microorganisms belong to the families of enterobacteriaceae and pseudomonads. Extremely rare, however, are cases where certain fastidious gramnegative bacteria such as hemophili, neisseria and others are the causative organisms. We report two cases of infective endocarditis due to Haemophilus parainfluenzae and to Neisseria gonorrhoeae. Despite their fastidious growth, both organisms could rapidly be isolated from venous blood cultures. Both were sensitive to ampicillin or penicillin respectively, and adequate antimicrobial therapy could early be initiated. As compared to reports in the literature both cases showed typical valve involvement and took a relatively typical course under medical treatment. The Haemophilus parainfluenzae endocarditis presented as a subacute illness following a tooth extraction and showed large vegetations on a prolapsed mitral valve. In contrast to the findings of others signs of slight renal involvement but no signs of major arterial embolization were noted. Medical treatment with ampicillin plus an aminoglycoside was effective as in most other reported cases. Vegetations were echocardiographically no longer seen after five weeks. The gonococcal endocarditis early led to destructive lesions of the aortic valve, significant regurgitation, vascular congestion and complicating pneumonia. Medical treatment alone was not effective despite the high susceptibility to antibiotics ot the strain isolated. As reported für the majority of cases reviewed in the literature early valve replacement became necessary for a favourable outcome.

[Use of digital subtraction angiography in localizing an anomalous pulmonary vein return in a case of congenital shunt disease]. / Der Nutzen der digitalen Subtraktionsangiographie zur Lokalisation einer fehlmündenden Lungenvene bei einem angeborenen Shuntvitium.

The exact analysis of an anomalous pulmonary venous return in patients with congenital shunt disease can lead to some difficulties when using the standard catheterization techniques. A left-sided anomalous pulmonary vein was suspected in a case with atrial and ventricular septal defects, but could not be evaluated during the catheterization procedure. The pathological vessel could be demonstrated exactly only by venous digital subtraction angiography. Thus, the digital subtraction angiography showed a diagnostic benefit in this complex shunt disease and should be considered in further problematic cases.